Emergent BioSolutions Inc. (NYSE:EBS) Stock Position Increased by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 1,314.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 273,287 shares of the biopharmaceutical company’s stock after buying an additional 253,960 shares during the quarter. Federated Hermes Inc. owned 0.52% of Emergent BioSolutions worth $1,864,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of EBS. Meeder Asset Management Inc. acquired a new stake in Emergent BioSolutions in the 2nd quarter valued at about $41,000. American Century Companies Inc. raised its holdings in shares of Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Emergent BioSolutions during the second quarter valued at approximately $969,000. Acadian Asset Management LLC lifted its stake in Emergent BioSolutions by 267.5% during the second quarter. Acadian Asset Management LLC now owns 108,566 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 79,028 shares during the last quarter. Finally, Verus Capital Partners LLC bought a new stake in Emergent BioSolutions during the second quarter worth approximately $68,000. Institutional investors own 78.40% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on EBS. Benchmark reaffirmed a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a report on Friday, August 16th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Down 6.3 %

EBS stock opened at $6.55 on Friday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06 and a quick ratio of 0.54. The firm has a market capitalization of $343.23 million, a P/E ratio of -0.59 and a beta of 1.60. Emergent BioSolutions Inc. has a 52-week low of $1.42 and a 52-week high of $15.10. The company’s 50 day simple moving average is $9.44 and its 200-day simple moving average is $6.16.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The firm had revenue of $254.70 million for the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same period last year, the firm earned ($1.06) earnings per share. As a group, equities research analysts anticipate that Emergent BioSolutions Inc. will post -1.98 EPS for the current year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.